Azienda Ospedaliero Universitaria di Sassari-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2022

  1. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers

    ESMO Open, Vol. 7, Núm. 2

  2. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

    The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621

  2. Pressure injury prediction models for critically-ill patients should consider both the case-mix and local factors

    Intensive and Critical Care Nursing

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  2. Predictors of responses to immune checkpoint blockade in advanced melanoma

    Nature Communications, Vol. 8, Núm. 1

  3. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936

2015

  1. Consensus nomenclature for CD8+ T cell phenotypes in cancer

    OncoImmunology, Vol. 4, Núm. 4

  2. “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013

    Cancer Immunology, Immunotherapy, Vol. 64, Núm. 1, pp. 131-135

2014

  1. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

    Journal of Translational Medicine, Vol. 12, Núm. 1

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

2010

  1. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

    Cancer Immunology, Immunotherapy